EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Defining the ATA-2025 ‘consider RAIT’ zone in older patients with N1b PTC

Ziqiang Wang, Xue Song, Tingting Wang, Yangyang Xie, Qiwei Du, Weijun Zhang, Nian Liu, Rongguo Li, Jiawei He iD

Endocrine-Related Cancer · 2026

DOI: 10.1530/erc-25-0420 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrine-Related Cancer, 2026. Verfasst von Ziqiang Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: The First People's Hospital of Xiaoshan District, Xiaoshan Affiliated Hospital of Wenzhou Medical University, Hangzhou, China. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Thyroid Cancer, Papillary, Iodine Radioisotopes. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The aim of this study was to quantify the cancer-specific death (CSD) benefit of radioactive iodine therapy (RAIT) in older patients with N1b differentiated thyroid carcinoma, a population designated by the ATA-2025 guideline as a ‘consider RAIT’ zone despite unproven mortality benefit, and to translate this recommendation into clinically actionable subgroups using a competing-risks framework. We used data from the Surveillance, Epidemiology, and End Results (SEER) programme (2004–2015) and analysed papillary thyroid carcinoma (PTC) cases aged ≥55 years with N1b, M0. After 1:1 propensity score matching, cumulative incidence function and Fine–Gray models evaluated associations between RAIT and CSD. Stratifications included tumour size, positive lymph node burden (PLN > 5), and ETE. A nomogram was developed for 1-, 3-, and 5-year CSD prediction, and absolute risk reduction (ARR) and number needed to treat (NNT) were estimated. Among 1,142 patients, 648 were matched (n = 324/group; median follow-up = 69 months). Five-year CSD was 14.1% without RAIT versus 5.1% with RAIT (P = 0.001), yielding ARR ≈ 9% and NNT ≈ 11. RAIT was independently protective (SHR 0.33, 95% CI: 0.14–0.76). Benefit concentrated in tumours 2–4 cm, PLN > 5, and ETE-positive strata. The nomogram showed strong discrimination and calibration. In patients aged ≥55 years with N1b PTC, RAIT confers measurable mortality benefit, most evident in 2–4 cm, PLN > 5, or ETE-positive disease. Integrating ARR, NNT, and a validated nomogram, this study converts the conceptual ‘consider RAIT’ into clinically actionable ‘RAIT-favoured’ and ‘RAIT-optional’ pathways.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsThyroid Cancer, PapillaryIodine RadioisotopesHumansFemaleMaleMiddle AgedAgedNomogramsSEER Program

Stichwörter der Autor:innen

competing risk analysiselderly patientsnomogrampapillary thyroid carcinomaradioactive iodine

Substanzen

Iodine Radioisotopes

Autor:innen und Institutionen

  • The First People's Hospital of Xiaoshan District, Xiaoshan Affiliated Hospital of Wenzhou Medical University, Hangzhou, China.
  • Department of Respiratory and Critical Care Medicine, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China.
  • Department of General Practice, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China.
  • Zhejiang Key Laboratory of Multi-Omics Precision Diagnosis and Treatment of Liver Diseases, Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Department of Breast Surgery, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China.

ORCID-Profile: Jiawei He

Zitieren

APA

Wang, Z., Song, X., Wang, T., Xie, Y., Du, Q., Zhang, W., Liu, N., Li, R., & He, J. (2026). Defining the ATA-2025 ‘consider RAIT’ zone in older patients with N1b PTC. Endocrine-Related Cancer. https://doi.org/10.1530/erc-25-0420

Vancouver

Wang Z, Song X, Wang T, Xie Y, Du Q, Zhang W, et al. Defining the ATA-2025 ‘consider RAIT’ zone in older patients with N1b PTC. Endocrine-Related Cancer. 2026. doi:10.1530/erc-25-0420

BibTeX
@article{Wang2026,
  author = {Wang, Ziqiang and Song, Xue and Wang, Tingting and Xie, Yangyang and Du, Qiwei and Zhang, Weijun and Liu, Nian and Li, Rongguo and He, Jiawei},
  title = {Defining the ATA-2025 ‘consider RAIT’ zone in older patients with N1b PTC},
  journal = {Endocrine-Related Cancer},
  year = {2026},
  doi = {10.1530/erc-25-0420}
}
Kostenlos starten →